Bessemer Group
ACAD icon

Bessemer Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Bessemer Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.8M Sell
150,309
-189
-0.1% -$4.16K 0.01% 671
2026
Q1 		$3.35M Buy
150,498
+149,789
+21,127% +$3.58M 0.01% 638
2025
Q4 		$19K Buy
709
+110
+18% +$2.63K ﹤0.01% 1888
2025
Q3 		$13K Buy
599
+244
+69% +$5.77K ﹤0.01% 1836
2025
Q2 		$8K Sell
355
-135
-28% -$2.51K ﹤0.01% 1877
2025
Q1 		$8K Buy
+490
New +$8.9K ﹤0.01% 1837
2024
Q4 		– Sell
-75
Closed -$1K – 2433
2024
Q3 		$1K Buy
+75
New +$1.25K ﹤0.01% 2308
2022
Q2 		– Sell
-191
Closed -$5K – 1857
2022
Q1 		$5K Hold
191
– – ﹤0.01% 1498
2021
Q4 		$4K Hold
191
– – ﹤0.01% 1613
2021
Q3 		$3K Hold
191
– – ﹤0.01% 1565
2021
Q2 		$5K Hold
191
– – ﹤0.01% 1422
2021
Q1 		$5K Buy
+191
New +$8.41K ﹤0.01% 1386
2017
Q1 		– Sell
-117
Closed -$3K – 1731
2016
Q4 		$3K Buy
+117
New +$3.1K ﹤0.01% 1797
2015
Q4 		– Sell
-10
Closed – – 1562
2015
Q3 		$0 Buy
+10
New +$416 ﹤0.01% 1614

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bessemer Group's ACAD Position: Q2 2026 in Review

Bessemer Group reduced its Acadia Pharmaceuticals (ACAD) stake by 0.13% in Q2 2026, selling an estimated $4.16K and leaving 150,309 shares worth $3.8M. The position accounts for 0.01% of the portfolio, ranked #671.

Bessemer Group first reported a position in ACAD in Q3 2015 and has held it in 14 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Bessemer Group held 150,309 shares of Acadia Pharmaceuticals worth $3.8M as of Q2 2026.
  • Bessemer Group sold 189 Acadia Pharmaceuticals shares in Q2 2026, an estimated $4.16K.
  • Acadia Pharmaceuticals made up 0.01% of Bessemer Group's portfolio in Q2 2026, its #671 holding.
  • Bessemer Group first reported a position in Acadia Pharmaceuticals in Q3 2015 and has held it in 14 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.